Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;2(7):338-349.
doi: 10.1016/j.trecan.2016.06.003.

Actionable molecular biomarkers in primary brain tumors

Verena Staedtke #  1   2 , Omar Dildar a Dzaye #  1   3   4 , Matthias Holdhoff #  1   5
Affiliations
Review

Actionable molecular biomarkers in primary brain tumors

Verena Staedtke et al. Trends Cancer. 2016 Jul.

Abstract

Recent genome-wide studies of malignancies of the central nervous system (CNS) have revolutionized our understanding of the biology of these tumors. This newly gained knowledge provides a wealth of opportunity for biomarker driven clinical research. To date, however, only few of the available molecular markers truly influence clinical decision-making and treatment. The most widely validated markers in neuro-oncology presently are: 1) MGMT promoter methylation as a prognostic and predictive marker in glioblastoma, 2) co-deletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas, 3) IDH1/2 mutations, and 4) select pathway-associated mutations. This article focuses on currently impactful biomarkers in adult and pediatric brain cancers and it provides a perspective on the direction of research in this field.

Keywords: BRAF mutation; Biomarker; IDH mutation; MGMT promoter methylation; co-deletion of 1p/19q; glioblastoma; glioma; medulloblastoma.

PubMed Disclaimer

References

    1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica. 2016;131(6):803–20. doi: 10.1007/s00401-016-1545-1. - PubMed
    1. Holdhoff M, Ye X, Blakeley JO, et al. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol. 110(2):279–85. doi: 10.1007/s11060-012-0968-3. - PubMed
    1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. doi: 1164382 [pii]10.1126/science.1164382. - PMC - PubMed
    1. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine. 2009;360(8):765–73. doi: 360/8/765 [pii] 10.1056/NEJMoa0808710. - PMC - PubMed
    1. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44. doi: 10.1038/nature08617. - PMC - PubMed

Publication types

Substances